Class information for:
Level 1: DORN VA MED//TUMOR DORMANCY//CONCOMITANT RESISTANCE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
20474 397 48.8 74%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
2793 2583 TUMOR DORMANCY//DORN VA MED//CONCOMITANT RESISTANCE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DORN VA MED Address 12 86% 2% 6
2 TUMOR DORMANCY Author keyword 11 28% 8% 33
3 CONCOMITANT RESISTANCE Author keyword 8 70% 2% 7
4 METASTASIS DEVELOPMENT Author keyword 4 75% 1% 3
5 TUMOUR DORMANCY Author keyword 4 36% 2% 8
6 CONCOMITANT TUMOR RESISTANCE Author keyword 2 67% 1% 2
7 INAPPROPRIATE GENE EXPRESSION Author keyword 2 67% 1% 2
8 MDA MB 435 BREAST CANCER CELL LINE Author keyword 2 67% 1% 2
9 MURINE LEUKAEMIA Author keyword 2 67% 1% 2
10 POLYOXIDONIUM Author keyword 2 67% 1% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 TUMOR DORMANCY 11 28% 8% 33 Search TUMOR+DORMANCY Search TUMOR+DORMANCY
2 CONCOMITANT RESISTANCE 8 70% 2% 7 Search CONCOMITANT+RESISTANCE Search CONCOMITANT+RESISTANCE
3 METASTASIS DEVELOPMENT 4 75% 1% 3 Search METASTASIS+DEVELOPMENT Search METASTASIS+DEVELOPMENT
4 TUMOUR DORMANCY 4 36% 2% 8 Search TUMOUR+DORMANCY Search TUMOUR+DORMANCY
5 CONCOMITANT TUMOR RESISTANCE 2 67% 1% 2 Search CONCOMITANT+TUMOR+RESISTANCE Search CONCOMITANT+TUMOR+RESISTANCE
6 INAPPROPRIATE GENE EXPRESSION 2 67% 1% 2 Search INAPPROPRIATE+GENE+EXPRESSION Search INAPPROPRIATE+GENE+EXPRESSION
7 MDA MB 435 BREAST CANCER CELL LINE 2 67% 1% 2 Search MDA+MB+435+BREAST+CANCER+CELL+LINE Search MDA+MB+435+BREAST+CANCER+CELL+LINE
8 MURINE LEUKAEMIA 2 67% 1% 2 Search MURINE+LEUKAEMIA Search MURINE+LEUKAEMIA
9 POLYOXIDONIUM 2 67% 1% 2 Search POLYOXIDONIUM Search POLYOXIDONIUM
10 SCREENING CONTROVERSY 2 67% 1% 2 Search SCREENING+CONTROVERSY Search SCREENING+CONTROVERSY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CONCOMITANT RESISTANCE 15 82% 2% 9
2 TUMOR DORMANCY 12 29% 9% 35
3 NONIMMUNOGENIC MURINE TUMORS 11 100% 2% 6
4 HUMAN LIPOSARCOMA 11 69% 2% 9
5 CANCER DORMANCY 6 40% 3% 12
6 MENOPAUSAL STATUS DEPENDENCE 6 100% 1% 4
7 RECURRENCE DYNAMICS 3 60% 1% 3
8 BALANCED PROLIFERATION 2 67% 1% 2
9 ISOGENIC MODEL 2 67% 1% 2
10 METASTATIC INEFFICIENCY 2 27% 2% 7

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The epigenetic/noncoding origin of tumor dormancy 2015 1 64 23%
Mechanisms of disseminated cancer cell dormancy: an awakening field 2014 18 143 18%
The effects of surgery on tumor growth: a century of investigations 2008 76 55 44%
Does tumour dormancy offer a therapeutic target? 2010 97 68 34%
Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases? 2005 73 26 35%
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients 2004 37 10 50%
Molecular mechanisms underlying tumor dormancy 2010 56 59 41%
The Dormancy Dilemma: Quiescence versus Balanced Proliferation 2013 12 39 38%
Models, mechanisms and clinical evidence for cancer dormancy 2007 420 130 12%
Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour 2004 24 32 50%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 DORN VA MED 12 86% 1.5% 6
2 STEWARD SPECIALTY PROJECTS CORP 2 50% 0.8% 3
3 ESTUDIOS ONCOL 1 16% 1.8% 7
4 EXCELLENCE CANC GENOM 1 30% 0.8% 3
5 DORN VET AFFAIRS MED 1 40% 0.5% 2
6 BIOL IMAGING CELL BIOL PHYSIOL 1 50% 0.3% 1
7 BIOSTAT BRANCHEPSNIH 1 50% 0.3% 1
8 BIOSTAT BRANCHNIH 1 50% 0.3% 1
9 CANC SYST BIOLST ELIZABETHS MED 1 50% 0.3% 1
10 CONSEJO NACL INVEST CIENT TECNCATEDRA INMUNOL 1 50% 0.3% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000150109 FERTILITY CYCLE//CHRONOEPIDEMIOLOGY//SCREENING CAMPAIGNS
2 0.0000096996 CIRCULATING TUMOR CELLS//DISSEMINATED TUMOR CELLS//CIRCULATING TUMOUR CELLS
3 0.0000090310 ENDOSTATIN//ANGIOSTATIN//COLLAGEN XVIII
4 0.0000088613 SURGICAL ORTHOTOPIC IMPLANTATION//ORTHOTOPIC IMPLANTATION//ORTHOTOPIC MOUSE MODELS
5 0.0000074804 NON COLORECTAL//STAGE IV BREAST CANCER//NON NEUROENDOCRINE
6 0.0000073369 BRMS1//BREAST CANCER METASTASIS SUPPRESSOR 1//FDN CANC METASTASIS
7 0.0000072014 MU MSV//CLA PTX//EPIDERMIS PROLIFERATION
8 0.0000070488 CARCINOCYTHEMIA//BONE MARROW CARCINOSIS//TUMOR BIOL METASTASIS BRANCH
9 0.0000061552 TUMOR BEARING STATE//AUTOIMMUNOTHERAPY//CD8 CELL REACTIVITY
10 0.0000059214 ANTIANGIOGENIC CANCER VACCINE//CELL PROTEOMIC FOOTPRINTING//HER1 VACCINE